Drug Shortages in the U.S. 2023

32 Pages

This report analyzes persistent drug shortages in the U.S., particularly affecting generic sterile injectables and essential medicines. It identifies root causes including low margins, manufacturing concentration, quality issues, and supply chain fragility. The report highlights the impact on patient care and provider burden, and calls for policy and market reforms to improve supply reliability, incentivize redundancy, and strengthen domestic manufacturing resilience.

Join for free to read

Report Trends in Drug Shortages and ANDA Approvals in the U.S.

Case Study SMITH DRUG

Report 2023 RCM Transformative Trends Report

Report The Use of Medicines in the U.S. 2023

More from IQVIA

Report Trends in Drug Shortages and ANDA Approvals in the U.S.

Report The Use of Medicines in the U.S. 2023

White Paper Mitigating Drug Shortages: Strategies for Resilient…

White Paper Artificial Intelligence in Drug Development

Report

Drug Shortages in the U.S. 2023

Drug Shortages in the U.S. 2023

You Might Also Like

More from IQVIA